Lead pharma rivals in drug access for poor
- Parliament LIVE: Expert committee to review use of pellet guns, says Rajnath
- Dalit fury spills over to Gujarat streets, 9 more try to end lives; CM meets family assaulted in Una
- Hit by campus protests, FTII makes new students sign ‘decorum, decency’ affidavit
- Dalits are 'soft target' for cow vigilantes: fact finding team
- Suspicious bag found inside Dubai-Amritsar SpiceJet flight
Drugmakers - led by GlaxoSmithKline and Johnson & Johnson - are stepping up efforts to ensure their medicines are available and affordable in poor countries, after being attacked in the past for not doing enough.
The Access to Medicines Index, which tracks the actions of the top 20 drugmakers, showed on Wednesday there had been an improvement across the board in the past two years, reflecting both commercial self-interest and a concern for reputation.
Still, the nonprofit group behind the index took companies to task for not being more open about the widespread outsourcing of clinical trials in overseas countries, where many studies are handled by contract research organisations (CROs).
The analysis found no company was fully transparent about all the CROs it used, and only four - Merck & Co, Sanofi , GlaxoSmithKline and Eisai - provided evidence of enforcing codes of conduct to ensure CRO trials met safety and ethical standards.
Companies are increasingly conducting clinical trials in eastern Europe, Asia and Latin America, where costs are often lower and patients easier to recruit.
Low cost, High voume
With emerging markets now a top priority for pharmaceutical companies worldwide, as sales in Western nations slow, firms are experimenting with a wide variety of low-cost, high-volume models to boost business.
As a result, Wim Leereveld, founder of the Amsterdam-based Access to Medicine Foundation, said companies were becoming much more organised internally in addressing the needs of low-income markets.
More companies are now adopting tiered pricing, with prices in poor countries sometimes reduced by 50 to 75 percent, although this varies considerably between companies, products and markets.
Britain's GlaxoSmithKline came top in the 2012 index, based on an assessment of performance across a range of activities, such as drug donation, patent policy, pricing and research.
Johnson & Johnson was second and Sanofi third, while Japanese drugmakers came bottom of the table.
- UN faces a crisis, but its new secretary general is unlikely to upset tradition
- South China Sea verdict has changed the ground rules for future engagement with China
- Empowering women through JAM
- Resolution of citizen grievances is an indicator of the performance of government departments
- Telescope: Grace and the lack of it
- The endeavour for a common civil law must be to end discrimination, and not stamp majority might